Handelen Eli Lilly & Co - LLY CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Spread | 1.67 | ||||||||
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.030779% | ||||||||
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | -0.013666% | ||||||||
Tijd van overnight-tarief | 22:00 (UTC) | ||||||||
Min. verhandelde hoeveelheid | 1 | ||||||||
Valuta | USD | ||||||||
Marge | 20% | ||||||||
Effectenbeurs | United States of America | ||||||||
Handelscommissie | 0% |
*Information provided by Capital.com
Eli Lilly and Co ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 337.93 |
Open* | 340.19 |
1-Jaarlijkse Verandering* | 39.71% |
Dagelijks bereik* | 334.52 - 340.19 |
52 wekelijks bereik | 231.87-384.44 |
Weekgemiddelde volume (10 dagen) | 3.98M |
Gemiddeld volume (3 maanden) | 59.59M |
Marktkapitalisatie | 322.19B |
P/E Ratio | 49.13 |
Uitstaande Aandelen | 950.18M |
Omzet | 28.54B |
EPS | 6.90 |
Dividend (opbrengst %) | 1.33302 |
Beta | 0.33 |
Volgende inkomsten datum | Apr 27, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
---|---|---|---|---|---|---|
Feb 3, 2023 | 337.93 | 5.58 | 1.68% | 332.35 | 342.09 | 328.30 |
Feb 2, 2023 | 330.39 | -2.41 | -0.72% | 332.80 | 334.80 | 316.14 |
Feb 1, 2023 | 342.15 | 1.23 | 0.36% | 340.92 | 345.40 | 336.80 |
Jan 31, 2023 | 343.91 | 5.17 | 1.53% | 338.74 | 344.11 | 338.74 |
Jan 30, 2023 | 340.18 | -1.86 | -0.54% | 342.04 | 347.28 | 339.15 |
Jan 27, 2023 | 341.77 | -2.99 | -0.87% | 344.76 | 347.70 | 341.32 |
Jan 26, 2023 | 347.65 | -2.14 | -0.61% | 349.79 | 351.79 | 346.30 |
Jan 25, 2023 | 349.26 | 7.35 | 2.15% | 341.91 | 349.50 | 341.91 |
Jan 24, 2023 | 345.92 | -16.82 | -4.64% | 362.74 | 364.89 | 339.80 |
Jan 23, 2023 | 341.82 | -2.04 | -0.59% | 343.86 | 345.86 | 339.80 |
Jan 20, 2023 | 345.80 | 1.01 | 0.29% | 344.79 | 348.73 | 341.12 |
Jan 19, 2023 | 350.82 | 1.39 | 0.40% | 349.43 | 355.30 | 349.43 |
Jan 18, 2023 | 351.45 | -4.05 | -1.14% | 355.50 | 358.73 | 351.25 |
Jan 17, 2023 | 357.38 | -1.09 | -0.30% | 358.47 | 361.50 | 356.17 |
Jan 13, 2023 | 361.23 | 6.08 | 1.71% | 355.15 | 362.95 | 355.15 |
Jan 12, 2023 | 358.72 | 3.25 | 0.91% | 355.47 | 360.15 | 351.69 |
Jan 11, 2023 | 359.86 | 7.67 | 2.18% | 352.19 | 361.49 | 348.71 |
Jan 10, 2023 | 352.54 | 5.75 | 1.66% | 346.79 | 352.96 | 342.22 |
Jan 9, 2023 | 349.45 | -13.34 | -3.68% | 362.79 | 364.60 | 348.43 |
Jan 6, 2023 | 362.71 | 4.92 | 1.38% | 357.79 | 366.20 | 356.41 |
Eli Lilly & Co Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Jaarlijks
- Per kwartaal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Totale inkomsten | 21222.1 | 19973.8 | 21493.3 | 22319.5 | 24539.8 | 28318.4 |
Inkomsten | 21222.1 | 19973.8 | 21493.3 | 22319.5 | 24539.8 | 28318.4 |
Kosten van opbrengsten, totaal | 5654.9 | 4447.7 | 4681.7 | 4721.2 | 5483.3 | 7312.8 |
Brutowinst | 15567.2 | 15526.1 | 16811.6 | 17598.3 | 19056.5 | 21005.6 |
Totale bedrijfskosten | 17763.3 | 17970.5 | 17958.8 | 17287.9 | 18481.8 | 22366.5 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 6452 | 5982.4 | 5975.1 | 6213.8 | 6121.2 | 6431.6 |
Onderzoek & Ontwikkeling | 5243.9 | 5096.2 | 5051.2 | 5595 | 6085.7 | 7025.9 |
Ongebruikelijke uitgaven (inkomsten) | 412.5 | 2444.2 | 2250.8 | 757.9 | 791.6 | 1596.2 |
Bedrijfsresultaat | 3458.8 | 2003.3 | 3534.5 | 5031.6 | 6058 | 5951.9 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | -76.5 | -58.6 | -83.2 | -320.2 | -326.6 | -137.5 |
Overige, Netto | -8.3 | 360.1 | 228.8 | 554.5 | 1498.5 | 341.1 |
Netto inkomen voor belastingen | 3374 | 2304.8 | 3680.1 | 5265.9 | 7229.9 | 6155.5 |
Netto inkomen na belastingen | 2737.6 | 4493.6 | 3325.9 | 4637.9 | 6193.7 | 5581.7 |
Netto inkomen voor extra. Posten | 2737.6 | 4493.6 | 3325.9 | 4637.9 | 6193.7 | 5581.7 |
Netto inkomen | 2737.6 | -204.1 | 3232 | 8318.4 | 6193.7 | 5581.7 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | 2737.6 | 4493.6 | 3325.9 | 4637.9 | 6193.7 | 5581.7 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | 2737.6 | -204.1 | 3232 | 8318.4 | 6193.7 | 5581.7 |
Verwaterd Netto Inkomen | 2737.6 | -204.1 | 3232 | 8318.4 | 6193.7 | 5581.7 |
Verwaterd Gewogen Gemiddelde Aandelen | 1061.82 | 1052.02 | 1033.67 | 935.684 | 912.505 | 911.681 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | 2.5782 | 4.27139 | 3.21757 | 4.95669 | 6.78758 | 6.12243 |
Dividends per Share - Common Stock Primary Issue | 2.04 | 2.08 | 2.25 | 2.58 | 2.96 | 3.4 |
Verwaterde Genormaliseerde Winst per Aandeel | 2.89874 | 6.15171 | 5.37021 | 5.70063 | 7.63447 | 7.79951 |
Totale buitengewone posten | -4697.7 | -93.9 | 3680.5 | 0 | 0 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Totale inkomsten | 6805.6 | 6740.1 | 6772.8 | 7999.9 | 7810 |
Inkomsten | 6805.6 | 6740.1 | 6772.8 | 7999.9 | 7810 |
Kosten van opbrengsten, totaal | 1878.6 | 1953.2 | 1430.8 | 2050.2 | 2072.1 |
Brutowinst | 4927 | 4786.9 | 5342 | 5949.7 | 5737.9 |
Totale bedrijfskosten | 5650.3 | 5336.7 | 5296.8 | 6082.7 | 5405.7 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 1576 | 1685.7 | 1577.9 | 1592 | 1557.9 |
Onderzoek & Ontwikkeling | 1684.8 | 1672.8 | 1708.9 | 1959.4 | 1610.1 |
Ongebruikelijke uitgaven (inkomsten) | 510.9 | 25 | 579.2 | 481.1 | 165.6 |
Bedrijfsresultaat | 1155.3 | 1403.4 | 1476 | 1917.2 | 2404.3 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | 219.2 | 133.9 | -323.4 | -167.2 | -503.3 |
Overige, Netto | 101.9 | 56.6 | 92.7 | 89.9 | 152.6 |
Netto inkomen voor belastingen | 1476.4 | 1593.9 | 1245.3 | 1839.9 | 2053.6 |
Netto inkomen na belastingen | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Netto inkomen voor extra. Posten | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Netto inkomen | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Verwaterd Netto Inkomen | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Verwaterd Gewogen Gemiddelde Aandelen | 912.4 | 910.4 | 910.8 | 911.624 | 906.4 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | 1.48542 | 1.52702 | 1.21882 | 1.89343 | 2.0994 |
Dividends per Share - Common Stock Primary Issue | 0.85 | 0.85 | 0.85 | 0.85 | 0.98 |
Verwaterde Genormaliseerde Winst per Aandeel | 2.02635 | 1.55448 | 1.80644 | 2.41408 | 2.28211 |
Totale buitengewone posten | 0 |
- Jaarlijks
- Per kwartaal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Totaal vlottende activa | 15101.4 | 19202.1 | 20549.6 | 13709.6 | 17462.1 | 18452.4 |
Geldmiddelen en kortetermijnbeleggingen | 6038.6 | 8034.1 | 7408.9 | 2438.5 | 3681.3 | 3908.6 |
Geldmiddelen & Equivalenten | 4582.1 | 6536.2 | 7320.7 | 2337.5 | 3657.1 | 3818.5 |
Korte Termijn Investeringen | 1456.5 | 1497.9 | 88.2 | 101 | 24.2 | 90.1 |
Totale Vorderingen, Netto | 4766.3 | 5262.2 | 5776.8 | 5541.5 | 6929 | 8127.2 |
Accounts Receivable - Trade, Net | 4029.4 | 4546.3 | 5776.8 | 4547.3 | 5875.3 | 6672.8 |
Total Inventory | 3561.9 | 4458.3 | 3098.1 | 3190.7 | 3980.3 | 3886 |
Prepaid Expenses | 734.6 | 1447.5 | 2036.7 | 2538.9 | 2871.5 | 2530.6 |
Total Assets | 38805.9 | 44981 | 43908.4 | 39286.1 | 46633.1 | 48806 |
Property/Plant/Equipment, Total - Net | 8252.6 | 8826.5 | 7996.1 | 8405 | 8681.9 | 8985.1 |
Property/Plant/Equipment, Total - Gross | 16777.6 | 18091.1 | 16663 | 17566.6 | 18252.6 | 18961.8 |
Accumulated Depreciation, Total | -8525 | -9264.6 | -8666.9 | -9161.6 | -9570.7 | -9976.7 |
Goodwill, Net | 3972.7 | 4370.1 | 1366.6 | 3679.4 | 3766.5 | 3892 |
Intangibles, Net | 4357.9 | 4029.2 | 1068 | 6618 | 7450 | 7691.9 |
Long Term Investments | 5207.5 | 5678.8 | 2005.4 | 1962.4 | 2966.8 | 3212.6 |
Other Long Term Assets, Total | 1913.8 | 2874.3 | 10922.7 | 4911.7 | 6305.8 | 6572 |
Total Current Liabilities | 10986.6 | 14535.9 | 11888.1 | 11775.2 | 12481.6 | 15052.7 |
Accounts Payable | 1349.3 | 1410.7 | 1207.1 | 1405.3 | 1606.7 | 1670.6 |
Accrued Expenses | 896.9 | 997.9 | 955.6 | 915.5 | 997.2 | 958.1 |
Notes Payable/Short Term Debt | 1299.3 | 2696.8 | 498.9 | 1494.2 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 638.1 | 1009.8 | 603.3 | 5.1 | 8.7 | 1538.3 |
Other Current Liabilities, Total | 6803 | 8420.7 | 8623.2 | 7955.1 | 9869 | 10885.7 |
Total Liabilities | 24798.2 | 33388.8 | 34079.7 | 36679.2 | 40991.5 | 39826.8 |
Total Long Term Debt | 8367.8 | 9940.5 | 9196.4 | 13817.9 | 16586.6 | 15346.4 |
Long Term Debt | 8358.8 | 9931.8 | 9196.4 | 13817.9 | 16586.6 | 15346.4 |
Capital Lease Obligations | 9 | 8.7 | ||||
Minority Interest | 72.8 | 75.7 | 1080.4 | 92.2 | 183.6 | 175.6 |
Other Liabilities, Total | 5371 | 8836.7 | 10602.1 | 8806.4 | 9639.8 | 7518.4 |
Total Equity | 14007.7 | 11592.2 | 9828.7 | 2606.9 | 5641.6 | 8979.2 |
Common Stock | 688.5 | 687.9 | 661 | 598.8 | 598.2 | 596.3 |
Additional Paid-In Capital | 5640.6 | 5817.8 | 6583.6 | 6685.3 | 6778.5 | 6833.4 |
Retained Earnings (Accumulated Deficit) | 16046.3 | 13894.1 | 11395.9 | 4920.4 | 7830.2 | 8958.5 |
Treasury Stock - Common | -80.5 | -75.8 | -69.4 | -60.8 | -55.7 | -52.7 |
Unrealized Gain (Loss) | 224 | 113.5 | 4.9 | 14.8 | 3.7 | |
Other Equity, Total | -8511.2 | -8845.3 | -8742.4 | -9541.7 | -9524.4 | -7360 |
Total Liabilities & Shareholders’ Equity | 38805.9 | 44981 | 43908.4 | 39286.1 | 46633.1 | 48806 |
Total Common Shares Outstanding | 1100.88 | 1100.01 | 1057.64 | 957.526 | 956.59 | 953.653 |
Other Current Assets, Total | 2229.1 | 0 | ||||
Deferred Income Tax | 1312.7 | 2187.5 | 2099.9 | 1733.7 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Totaal vlottende activa | 16604.5 | 17295.5 | 17808.3 | 18452.4 | 16964.7 |
Geldmiddelen en kortetermijnbeleggingen | 3051.4 | 3271.2 | 3825.3 | 3908.6 | 2568.3 |
Geldmiddelen & Equivalenten | 3002.4 | 3220 | 3788.2 | 3818.5 | 2459.2 |
Korte Termijn Investeringen | 49 | 51.2 | 37.1 | 90.1 | 109.1 |
Totale Vorderingen, Netto | 6658.6 | 6902.8 | 7025 | 8127.2 | 7805.7 |
Accounts Receivable - Trade, Net | 5592.8 | 5829.4 | 5914.3 | 6672.8 | 6322.5 |
Total Inventory | 3660.8 | 3824.9 | 3907.4 | 3886 | 3893 |
Prepaid Expenses | 3233.7 | 3296.6 | 3050.6 | 2530.6 | 2697.7 |
Total Assets | 46838.3 | 47809 | 48187 | 48806 | 46919.3 |
Property/Plant/Equipment, Total - Net | 8630.1 | 8855.5 | 8920.4 | 8985.1 | 9102.7 |
Property/Plant/Equipment, Total - Gross | 18273.5 | 18697.7 | 18883.2 | 18961.8 | 19241 |
Accumulated Depreciation, Total | -9643.4 | -9842.2 | -9962.8 | -9976.7 | -10138.3 |
Goodwill, Net | 3877.4 | 3884.2 | 3884.1 | 3892 | 3892 |
Intangibles, Net | 8087.8 | 7985.4 | 7887.7 | 7691.9 | 7482.4 |
Long Term Investments | 3232.4 | 3474.9 | 3350.5 | 3212.6 | 2727.3 |
Other Long Term Assets, Total | 6406.1 | 6313.5 | 6336 | 6572 | 6750.2 |
Total Current Liabilities | 11714.2 | 15093.2 | 13682 | 15052.7 | 13386 |
Accounts Payable | 1639.6 | 1597.8 | 1566.8 | 1670.6 | 1433.3 |
Accrued Expenses | 649.9 | 755.5 | 836.6 | 958.1 | 693.1 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 4.9 | 1778.5 | 1563 | 1538.3 | 1355.9 |
Other Current Liabilities, Total | 9419.8 | 10961.4 | 9715.6 | 10885.7 | 9903.7 |
Total Liabilities | 39939.6 | 41364.6 | 40430 | 39826.8 | 37588.5 |
Total Long Term Debt | 16199.6 | 14736.6 | 15522.4 | 15346.4 | 15152.9 |
Long Term Debt | 16199.6 | 14736.6 | 15522.4 | 15346.4 | 15152.9 |
Deferred Income Tax | 2200.6 | 1857.3 | 1632.5 | 1733.7 | 1286.1 |
Minority Interest | 200.6 | 219.1 | 197.1 | 175.6 | 131.2 |
Other Liabilities, Total | 9624.6 | 9458.4 | 9396 | 7518.4 | 7632.3 |
Total Equity | 6898.7 | 6444.4 | 7757 | 8979.2 | 9330.8 |
Common Stock | 599.7 | 598.1 | 598.2 | 596.3 | 594.1 |
Additional Paid-In Capital | 6579.2 | 6669.2 | 6758 | 6833.4 | 6656.3 |
Retained Earnings (Accumulated Deficit) | 9181.3 | 8530.1 | 9639.4 | 8958.5 | 9369.4 |
Treasury Stock - Common | -52.7 | -52.7 | -52.7 | -52.7 | -50.5 |
Unrealized Gain (Loss) | 4.5 | 9.1 | 6.8 | 3.7 | -18.1 |
Other Equity, Total | -9413.3 | -9309.4 | -9192.7 | -7360 | -7220.4 |
Total Liabilities & Shareholders’ Equity | 46838.3 | 47809 | 48187 | 48806 | 46919.3 |
Total Common Shares Outstanding | 959.019 | 956.575 | 956.589 | 953.653 | 950.155 |
- Jaarlijks
- Per kwartaal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Netto-inkomen/Beginsaldo | 2737.6 | -204.1 | 3232 | 8318.4 | 6193.7 | 5581.7 |
Geldmiddelen uit Operationele Activiteiten | 4851 | 5615.6 | 5524.5 | 4836.6 | 6499.6 | 7260.7 |
Geldmiddelen uit Operationele Activiteiten | 1496.6 | 1567.3 | 1609 | 1232.6 | 1323.9 | 1547.6 |
Deferred Taxes | 439.5 | -787.9 | 326.8 | 62.4 | -134.5 | -802.3 |
Niet-Geldelijke Posten | 661.4 | 1835.4 | 2735.4 | -3089.6 | -136.1 | 1956.3 |
Cash Taxes Paid | 700.6 | 246.5 | 1101.5 | 1180.5 | 954.6 | 1598.8 |
Contant Betaalde Rente | 146.4 | 192.7 | 223.8 | 305.5 | 345.8 | 338 |
Veranderingen in het Operationeel Kapitaal | -484.1 | 3204.9 | -2378.7 | -1687.2 | -747.4 | -1022.6 |
Geldmiddelen uit Investeringsactiviteiten | -3139.1 | -3783.6 | 1906 | -8082.9 | -2258.9 | -2762.3 |
Kapitaaluitgaven | -1092 | -2163.6 | -3018.2 | -1353.5 | -2029.1 | -1873.2 |
Overige Cash Flow investeringsposten, Totaal | -2047.1 | -1620 | 4924.2 | -6729.4 | -229.8 | -889.1 |
Geldmiddelen uit Financieringsactiviteiten | -559.8 | 142.6 | -5904.9 | -2324.5 | -3137.1 | -4131.3 |
Financiering van Cash Flow Posten | -300.8 | -364.4 | -372.8 | -200.1 | -241.6 | -295.9 |
Total Cash Dividends Paid | -2158.5 | -2192.1 | -2311.8 | -2409.8 | -2687.1 | -3086.8 |
Uitgifte (Aflossing) van aandelen, netto | -600.1 | -299.8 | -2491 | -4400 | -500 | -1250 |
Uitgifte (Aflossing) van Schulden, Netto | 2499.6 | 2998.9 | -729.3 | 4685.4 | 291.6 | 501.4 |
Wisselkoerseffecten | -236.4 | -20.5 | -63.6 | -89.9 | 216 | -205.7 |
Nettowijziging in Geldmiddelen | 915.7 | 1954.1 | 1462 | -5660.7 | 1319.6 | 161.4 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 1355.3 | 2745.5 | 3855.6 | 5581.7 | 1902.9 |
Cash From Operating Activities | 1697.4 | 3472.9 | 5104.2 | 7260.7 | 2499.2 |
Cash From Operating Activities | 350.3 | 719.6 | 1101.9 | 1547.6 | 435.7 |
Deferred Taxes | -119.1 | -413.8 | -709.8 | -802.3 | -506.6 |
Non-Cash Items | 213.7 | 303.2 | 1404.6 | 1956.3 | 712.7 |
Changes in Working Capital | -102.8 | 118.4 | -548.1 | -1022.6 | -45.5 |
Cash From Investing Activities | -1283.5 | -1766.8 | -2383.3 | -2762.3 | -1013.8 |
Capital Expenditures | -492.1 | -1023.4 | -1479 | -1873.2 | -857.2 |
Other Investing Cash Flow Items, Total | -791.4 | -743.4 | -904.3 | -889.1 | -156.6 |
Cash From Financing Activities | -1058.4 | -2141.6 | -2604.8 | -4131.3 | -2878.3 |
Financing Cash Flow Items | -279.9 | -294.8 | -295.3 | -295.9 | -282.4 |
Total Cash Dividends Paid | -774.8 | -1543.1 | -2313.5 | -3086.8 | -885.5 |
Issuance (Retirement) of Stock, Net | 0 | -500 | -500 | -1250 | -1500 |
Issuance (Retirement) of Debt, Net | -3.7 | 196.3 | 504 | 501.4 | -210.4 |
Foreign Exchange Effects | -10.2 | -1.6 | 15 | -205.7 | 33.6 |
Net Change in Cash | -654.7 | -437.1 | 131.1 | 161.4 | -1359.3 |
Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
---|---|---|---|---|---|---|
Lilly Endowment, Inc. | Investment Advisor | 10.8347 | 102948810 | -210000 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 7.6008 | 72221213 | 994066 | 2022-09-30 | LOW |
PNC Wealth Management | Investment Advisor | 5.4451 | 51738161 | -44061 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.2364 | 40253792 | 58949 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 3.5343 | 33582472 | 168444 | 2022-09-30 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 3.3604 | 31929656 | 631015 | 2022-09-30 | LOW |
Capital World Investors | Investment Advisor | 3.0547 | 29024874 | 282228 | 2022-09-30 | LOW |
PRIMECAP Management Company | Investment Advisor | 2.9486 | 28017155 | -421333 | 2022-09-30 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 2.5054 | 23805927 | 3379269 | 2022-09-30 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 2.2989 | 21843288 | -1593968 | 2022-09-30 | LOW |
State Farm Insurance Companies | Insurance Company | 1.8324 | 17410725 | 0 | 2022-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.6935 | 16091249 | 373938 | 2022-09-30 | LOW |
Jennison Associates LLC | Investment Advisor/Hedge Fund | 1.0592 | 10064742 | -293324 | 2022-09-30 | LOW |
JP Morgan Asset Management | Investment Advisor | 0.866 | 8228610 | 173535 | 2022-09-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.8435 | 8014500 | -246196 | 2021-12-31 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7439 | 7068030 | -132558 | 2022-09-30 | LOW |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.6244 | 5933104 | -307204 | 2022-09-30 | LOW |
Capital International Investors | Investment Advisor | 0.5893 | 5599174 | 637189 | 2022-09-30 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.5885 | 5591703 | -216451 | 2022-09-30 | LOW |
BofA Global Research (US) | Research Firm | 0.5868 | 5576096 | -144521 | 2022-09-30 | LOW |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com GroupHandelaren
Actieve klanten per maand
Maandelijks beleggingsvolume
Opgenomen per maand
Handelscalculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Eli Lilly Company profile
Over Eli Lilly & Co
Eli Lilly and Company is een bedrijf dat geneesmiddelen produceert. Het bedrijf houdt zich bezig met de ontdekking, ontwikkeling, productie, marketing en verkoop van farmaceutische producten over de hele wereld. De diabetesproducten van het bedrijf omvatten Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta en Trulicity. De oncologieproducten van het bedrijf omvatten Alimta, Cyramza, Erbitux, Retevmo, Tyvyt en Verzenio. De immunologieproducten van de Vennootschap bestaan uit Olumiant en Taltz. Haar neurowetenschapsproducten omvatten Cymbalta, Emgality, Reyvow en Zyprexa. Haar andere therapieën bestaan uit Bamlanivimab, etesevimab, Cialis en Forteo. De onderneming vervaardigt en distribueert haar producten via vestigingen in de Verenigde Staten, inclusief Puerto Rico, en een achttal andere landen. Haar producten worden in ongeveer 120 landen verkocht. Onder haar dochterondernemingen bevinden zich onder meer Acanthas Pharma, Inc., Alnara Pharmaceuticals, Inc., ARMO Biosciences, Inc. en Avid Radiopharmaceuticals, Inc.
Industry: | Pharmaceuticals (NEC) |
Lilly Corporate Ctr
Drop Code 1094
INDIANAPOLIS
INDIANA 46285-0001
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 485.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen